A Single-arm, Open-label, Single-center Study to Evaluate the Safety and Tolerability of Intravenous GEN6050X Gene Therapy in Ambulatory Boys With Duchenne Muscular Dystrophy (DMD)

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 16 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

16 Sep 2024 New trial record
09 Sep 2024 According to a GenAssist Ltd media release, the IND filing of GEN6050X in China is expected in November 2024.
09 Sep 2024 According to a GenAssist Ltd media release, company announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com